PIII, US7444132044

P3 Health Partners stock fell 8.91 percent as Q2 revenue grew

Published on 10/07/2026 at 05:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

P3 Health Partners stock fell 8.91 percent to USD 5.62 on October 6, 2026, after a volatile period for the healthcare operator. Q2 revenue grew 8.6 percent year over year, while analysts list an average USD 18 target.

PIII, US7444132044, Illustration mit AI erstellt.

P3 Health Partners stock (ISIN US7444132044) was last at USD 5.62 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 8.91 percent from USD 6.17. The latest reported quarter combined revenue growth with a 10.7 percent operating margin, giving investors a sharper operating benchmark than the share price alone.

Q2 revenue reached USD 386.0 million

According to ToAlpha, P3 Health Partners generated USD 386.0 million in Q2 2026 revenue, up 8.6 percent year over year. The same quarterly summary lists diluted EPS of negative USD 0.63 and a 10.7 percent operating margin for the period filed on August 10, 2026.

The operating comparison matters because Q1 2026 revenue was USD 386.4 million, making the second quarter broadly stable sequentially while the year-over-year rate remained positive. P3's investor-relations page identifies the quarter as ended June 30, 2026 and describes the company as a physician-led population health management provider.

Financing adds a capital constraint

On September 11, 2026, P3 Health Partners announced an agreement with affiliates of Chicago Pacific Founders for up to USD 70 million of preferred equity and warrant units, according to Investing.com. The structure gives the company additional capital access, while the preferred securities and warrants also increase the importance of dilution and funding terms.

The balance sheet adds another measurable counter-factor. Cash stood at USD 21.3 million at June 30, 2026, while operating cash flow was negative USD 61.9 million in Q2, according to the quarterly financial data. That contrast places cash conversion alongside revenue growth as the central operating question.

Analysts see a wide target spread

Investing.com lists two analysts with a 12-month consensus target of USD 18, a high target of USD 23 and a low target of USD 13. The published ratings include Hold from TD Cowen and Buy from Lake Street, with the latest listed TD Cowen target at USD 13 on August 13, 2026.

The spread from USD 13 to USD 23 shows how differently analysts frame the balance between population-health growth, financing needs and cash usage. For investors, the next assessment point is whether stable quarterly revenue can translate into improving cash generation.

PIII stock remains below its yearly high

At USD 5.62 on Nasdaq on October 6, 2026, the stock stood below its 52-week high of USD 16.89 and above its 52-week low of USD 1.52. Market capitalization was USD 18.4 million and volume was 10,133 shares on the same date.